This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.

Actelion moves for judgment against US antitrust case over Tracleer

( February 20, 2024, 22:31 GMT | Official Statement) -- MLex Summary: Actelion Pharmaceuticals moved for a summary judgment against US antitrust claims accusing it of delaying entry of a generic version of the hypertension drug Tracleer. “Plaintiff in this antitrust case seeks to condemn—and capitalize on—Actelion’s compliance with mandatory [Food and Drug Administration] regulations put in place to protect patient safety. But plaintiff fails to satisfy the most basic elements of an antitrust claim. This failure is not surprising. The antitrust laws do not punish compliance with mandatory regulatory obligations, the only conduct plaintiff challenges here,” it argued....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections